GlassScriptPhysician profile
Jeffrey MD Goldstein
NPI 1689848897
$65,987.91
in general payments reported to CMS, 2019-2025
11 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $5,825 · 2021: $17K · 2022: $11.74 · 2024: $50.66 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $267.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $43,694.49 | 2019-2021 | |
| Arthrex, INC. | $13,006.94 | 2019-2020 | |
| Globus Medical, INC. | $8,529.73 | 2019-2020 | |
| Stryker Corporation | $297.27 | 2019-2025 | Mako |
| Nuvasive, INC. | $157.14 | 2019 | |
| Depuy Synthes Sales INC. | $155.62 | 2019 | |
| Medacta USA, INC. | $86.00 | 2025 | Gmk Sphere |
| Vertex Pharmaceuticals Incorporated | $30.97 | 2025 | |
| Davol INC. | $18.01 | 2024 | |
| Kci USA, INC. | $11.74 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$616,379.53 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.